Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof

Patent metadata

Field	Value
Publication number	US-10087175-B2
Application number	US-201515301188-A
Country	US
Kind code	B2
Filing date	Apr 1, 2015
Priority date	Apr 1, 2014
Publication date	Oct 2, 2018
Grant date	Oct 2, 2018

Abstract

Methods and compositions for treating cancers such as pancreatic cancer and synovial sarcoma are disclosed. Compounds comprising a sigma-2 receptor-binding moiety and a ferroptosis-inducing moiety are described. At least one described molecular species exhibits an IC 50 value below 5 μM against human pancreatic cancer cells in vitro. Administration of this species promoted shrinkage of pancreatic cancer tumors in a murine model system in vivo, and led to 100% survival of experimental animals over a time course in which control therapies provided only 30% or 40% survival. Methods of synthesis of molecular species are also disclosed.

First claim

What is claimed is:

1. A compound of structural Formula IV

or salt thereof, wherein n is an integer chosen from 1, 2, 3, 4, and 5, and R 2 is H or methyl.

2. A compound or a salt thereof in accordance with claim 1 , wherein n=1 and R 2 is H.

3. A compound or a salt thereof in accordance with claim 1 , wherein n=5 and R 2 is H.

4. A compound or a salt thereof in accordance with claim 1 , wherein the salt is an oxalate or a hydrochloride salt.

5. A compound chosen from:

6. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

7. A method of treating a pancreatic cancer or a synovial sarcoma in a subject in need thereof, comprising the step of administering to the subject a therapeutically effective amount of a compound of claim 1 , or a salt thereof.

8. The method according to claim 7 , wherein the subject is a human.

9. A method of treating a pancreatic cancer or a synovial sarcoma in a subject in need thereof, comprising administering the compound or salt thereof is the compound or salt thereof of claim 2 .

10. A method of treating a pancreatic cancer or a synovial sarcoma in a subject in need thereof, comprising administering the compound or salt thereof is the compound or salt thereof of claim 3 .

11. A method of treating a pancreatic cancer or a synovial sarcoma in a subject in need thereof, comprising the sequential or co-administration of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and an additional anticancer drug.

12. The method according to claim 11 , wherein the anticancer drug is chosen from an alkylating agent, anthracycline, antimetabolite agent, crosslinking agent, DNA replication inhibitor, intercalator, microtubule disruptor, PARP inhibitor, radiomimetic agent, radiosensitizer, strand break agent, and topoisomerase II inhibitor.

13. The method according to claim 11 , wherein the anticancer drug is chosen from aminoglutethimide, amsacrine, anastrozole, asparaginase, barasertib, bcg, bicalutamide, bleomycin, buserelin, busulfan, campothecin, capecitabine, carboplatin, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ironotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, olaparib, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, perifosine, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, sorafenib, streptozocin, sunitinib, suramin, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, and vinorelbine.

14. The method of claim 11 , wherein the method further comprises administering radiation therapy.

15. The method of claim 11 , wherein the method further comprises administering surgery, thermoablation, focused ultrasound therapy, cryotherapy, or any combination thereof.

16. A compound or a salt thereof in accordance with claim 2 , wherein the salt is an oxalate or a hydrochloride salt.

17. A compound or a salt thereof in accordance with claim 3 , wherein the salt is an oxalate or a hydrochloride salt.

18. A pharmaceutical composition comprising the compound of claim 2 and one or more pharmaceutically acceptable excipients, adjuvants, or vehicles.

19. A pharmaceutical composition comprising the compound of claim 3 and one or more pharmaceutically acceptable excipients, adjuvants, or vehicles.

20. A pharmaceutical composition comprising the compound of claim 4 and one or more pharmaceutically acceptable excipients, adjuvants, or vehicles.

21. A pharmaceutical composition comprising the compound of claim 16 and one or more pharmaceutically acceptable excipients, adjuvants, or vehicles.

22. A pharmaceutical composition comprising the compound of claim 17 and one or more pharmaceutically acceptable excipients, adjuvants, or vehicles.

23. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 6 to a patient in need thereof.

24. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 18 to a patient in need thereof.

25. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 19 to a patient in need thereof.

26. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 20 to a patient in need thereof.

27. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 21 to a patient in need thereof.

28. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 22 to a patient in need thereof.

Assignees

• Univ Washington

Inventors

• Hawkins William
• Mach Robert
• Spitzer Dirk
• Vangveravong Suwanna
• Van Tine Brian

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07D471/08

  Bridged systems · CPC title

• A61K31/517

  ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title

• A61K31/496

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title